Control Bionics has locked in $9.5 million through a discounted share placement, complemented by a $0.5 million Share Purchase Plan, to back its commercial growth and technology development.
- Placement priced at $0.075 per share, 14.5% discount to VWAP
- Two-tranche placement with second tranche needing shareholder approval
- Directors to receive shares subject to approval
- SPP offers eligible shareholders up to $30,000 at placement price
- Funds earmarked for commercial expansion, R&D, and working capital
Placement Raises $9.5 Million at Discounted Price
Control Bionics Limited (ASX:CBL) has secured firm commitments for a $9.5 million placement priced at $0.075 per share, representing a 14.5% discount to the five-day volume weighted average price (VWAP) up to 23 June 2026. The placement will be issued in two tranches, with the first tranche of approximately 29.6 million shares settled under existing placement capacity and the second tranche of about 96.7 million shares subject to shareholder approval at a general meeting expected in early August. This second tranche includes roughly 4.3 million shares earmarked for directors, pending approval.
Share Purchase Plan Opens to Eligible Investors
Alongside the placement, Control Bionics is launching a non-underwritten Share Purchase Plan (SPP) targeting up to $500,000. Eligible shareholders in Australia and New Zealand can apply for up to $30,000 worth of shares at the same discounted price of $0.075. The SPP opens on 2 July and closes on 14 July, with allotment and trading of new shares expected in late July. The company retains discretion to scale back applications if demand exceeds the target.
Proceeds to Accelerate Commercialisation and Technology
The total $10 million capital raise will bolster Control Bionics’ balance sheet, supporting its commercial expansion, platform and medical technology development, including clinical research, and strategic business initiatives. Specifically, $3.5 million is allocated to commercial growth and capability build-out, $1.5 million to technology and clinical research, another $1.5 million to strategic opportunities, and $2.8 million to operating cash requirements and working capital.
Directors’ Participation and Shareholder Meeting
The planned issue of shares to directors, totaling just over 4.25 million, highlights insider confidence but remains contingent on shareholder approval. The general meeting slated for 6 August will determine the fate of the second tranche and director allocations. Investors will be watching closely for the outcome, which will impact the company’s capital structure, potentially increasing shares on issue to approximately 545.3 million if the placement and SPP are fully subscribed.
Strategic Positioning in Neurotechnology Markets
Control Bionics continues to expand its footprint in assistive communication, rehabilitation, and sports performance markets with its patented NeuroNode and NeuroStrip technologies. The company’s wireless EMG devices translate neural signals into actionable commands, enabling faster and less fatiguing communication for users with complex needs. This capital raise arrives as Control Bionics builds on recent regulatory and distribution milestones across North America, Europe, and Asia, positioning the company for broader commercial traction.
Bottom Line?
The success of the shareholder vote in August and uptake of the SPP will be pivotal in determining how swiftly Control Bionics can execute its growth strategy backed by this fresh capital.
Questions in the middle?
- Will shareholder approval for the second tranche and director shares be secured without issue?
- How will the company balance dilution concerns with the need for growth capital?
- What commercial milestones will Control Bionics target with the new funds over the next 12 months?